Adjuvant doxorubicin vs metronomic cyclophosphamide and meloxicam vs surgery alone for cats with mammary carcinomas: A retrospective study of 137 cases.
Adjuvants, Immunologic
Animals
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma
/ drug therapy
Cat Diseases
/ drug therapy
Cats
Chemotherapy, Adjuvant
/ veterinary
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Mammary Neoplasms, Animal
/ drug therapy
Mastectomy
/ veterinary
Meloxicam
/ administration & dosage
Retrospective Studies
Survival Rate
adjuvant chemotherapy
cat
mammary tumours
metronomic chemotherapy
prognosis
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
10
10
2020
received:
18
03
2020
accepted:
29
10
2020
pubmed:
4
11
2020
medline:
27
1
2022
entrez:
3
11
2020
Statut:
ppublish
Résumé
This study aims to evaluate the efficacy and side effects of low dose cyclophosphamide chemotherapy plus meloxicam as an adjuvant treatment, compared with high dose doxorubicin or surgery alone in cats with mammary carcinoma. Medical records of 228 female cats treated for mammary carcinoma between 2008 and 2018, were reviewed in eight veterinary institutions. Only cats with complete tumour staging and radical mastectomy were included in the study. One hundred and thirty-seven cats were divided into three treatment groups: group 1 (n = 80) cats treated with surgery, group 2 (n = 34) cats that had surgery and adjuvant treatment with doxorubicin, and group 3 (n = 23) cats with surgery and adjuvant treatment with low dose metronomic cyclophosphamide and meloxicam. The study endpoints were disease free interval (DFI) and overall survival (OS). Toxicity was evaluated according to the VCOG-CTCAE criteria. The median DFI was 270, 226 and 372 days in groups 1, 2 and 3, respectively. The median OS was 338 (group 1), 421 (group 2) and 430 (group 3) days. The differences between groups were not significant (DFI P = .280 and OS P = .186). Toxicity was observed in 52.9% (n = 18) of cats in group 2 and 39.1% (n = 9) of cats in group 3, with mild to moderate intensity. Differences were not significant (P = .306). In conclusion, adjuvant chemotherapy treatment did not improve survival and the overall benefit remains unproven. Randomized prospective trials are necessary to clarify the effectiveness of adjuvant chemotherapy treatment for feline mammary carcinomas.
Substances chimiques
Adjuvants, Immunologic
0
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Meloxicam
VG2QF83CGL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
714-723Subventions
Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDB/00211/2020
Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDB/04033/2020
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Zappulli V, Rasotto R, Caliari D, et al. Prognostic evaluation of feline mammary carcinomas: a review of the literature. Vet Pathol. 2015;52(1):46-60.
Giménez F, Hecht S, Craig LE, Legendre AM. Early detection, aggressive therapy: optimizing the management of feline mammary masses. J Feline Med Surg. 2010;12(3):214-224.
Caliari D, Zappulli V, Rasotto R, et al. Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. BMC Vet Res. 2014;10:185.
Cannon CM. Cats, cancer and comparative oncology. Vet Sci. 2015;2(3):111-126.
Novosad CA, Bergman PJ, O'Brien MG, et al. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. J Am Anim Hosp Assoc. 2006;42(2):110-120.
MacEwen EG, Hayes AA, Harvey HJ, Patnaik AK, Mooney S, Passe S. Prognostic factors for feline mammary tumors. J Am Vet Med Assoc. 1984;185(2):201-204.
Morris J. Mammary tumours in the cat: size matters, so early intervention saves lives. J Feline Med Surg. 2013;15(5):391-400.
Itoh T, Kadosawa T, Mochizuki M, Matsunaga S, Nishimura R, Sasaki N. Prognosis of malignant mammary tumor in 53 cats. J Vet Med Sci. 1996;58(8):723-726.
Seixas F, Palmeira C, Pires MA, Bento MJ, Lopes C. Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet J. 2011;187(1):65-71.
Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol. 1998;119(3):263-275.
McNeill CJ, Sorenmo KU, Shofer FS, et al. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. J Vet Intern Med. 2009;23(1):123-129.
Borrego JF, Cartagena JC, Engel J. Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007). Vet Comp Oncol. 2009;7(4):213-221.
Campos CBD, Nunes FC, Lavalle GE, Cassali GD. Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging. In Vivo. 2014;28(5):863-866.
Cunha SC, Corgozinho KB, Souza HJ, Silva KV, Ferreira AMR. Adjuvant chemotherapy with mitoxantrone for cats with mammary carcinomas treated with radical mastectomy. J Feline Med Surg. 2015;17(12):1000-1004.
Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol. 2019;2019:1-31.
Gaspar TB, Henriques J, Marconato L, Queiroga FL. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field. Vet Comp Oncol. 2018;16(1):2-11.
Leo C, Stell A, Borrego J, Martinez de Merlo E, Ruess-Melzer K, Lara-Garcia A. Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia. J Feline Med Surg. 2014;16(8):671-678.
Mander KA, Finnie JW. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. Aust Vet J. 2018;96(10):371-378.
Rabanal C, Ruiz R, Neciosup S, Gomez H. Metronomic chemotherapy for non-metastatic triple negative breast cancer: selection is the key. World J Clin Oncol. 2017;8(6):437-446.
Banys-Paluchowski M, Schütz F, Ruckhäberle E, Krawczyk N, Fehm T. Metronomic chemotherapy for metastatic breast cancer - a systematic review of the literature. Geburtshilfe Frauenheilkd. 2016;76(5):525-534.
Misdorp W, Else RW, Hellmén E, Lipscomb TP. Histological classification of mammary tumors of the dog and the cat. In: World Health Organization, ed. International Histological Classification of Tumors of Domestic Animals. Second Series. Vol 7. Washington, DC: Armed Forces Institute of Pathology, American Registry of Pathology; 1999:11-56.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410.
Gemignani F, Mayhew PD, Giuffrida MA, et al. Association of surgical approach with complication rate, progression-free survival time, and disease-specific survival time in cats with mammary adenocarcinoma: 107 cases (1991-2014). J Am Vet Med Assoc. 2018;252(11):1393-1402.
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417-446.
Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol. 2015;12(11):631-644.
Munzone E, Colleoni M. Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. Cancer Lett. 2017;400:259-266.
Hughes K, Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J. 2012;194(1):19-26.
Millanta F, Lazzeri G, Vannozzi I, Viacava P, Poli A. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Vet Pathol. 2002;39(6):690-696.
Millanta F, Citi S, Della Santa D, Porciani M, Poli A. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat. 2006;98(1):115-120.
Carvalho MI, Pires I, Prada J, et al. High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study. Vet Comp Oncol. 2017;15(2):619-631.
Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res. 2003;37:179-192.
Pang LY, Argyle SA, Kamida A, Morrison KO, Argyle DJ. The long-acting COX-2 inhibitor mavacoxib (TrocoxilTM) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. BMC Vet Res. 2014;10:1-11.
Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci. 2006;80(3):308-316.
Sorenmo KU, Goldschmidt MH, Shofer FS, Goldkamp C, Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol. 2004;2(1):13-23.
Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med. 2003;17(2):136-144.
Liu F-S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan J Obstet Gynecol. 2009;48(3):239-244.
Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105-127.
Chun K-H, Park JH, Fan S. Predicting and overcoming chemotherapeutic resistance in breast cancer. Adv Exp Med Biol. 2017;1026:59-104.
Soares M, Correia J, Peleteiro MC, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37(3):4053-4064.
Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer. 2013;13:403.
Dagher E, Royer V, Buchet P, et al. Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer. BMC Cancer. 2019;19:1267.
Yamada A, Ishikawa T, Ota I, et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat. 2013;137(3):773-782.
Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17(2):152-163.
Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110-122.
Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Research. 2019;8:1-11.
Yee-Ka Cheng K, Krockenberger M, Bennett P. Use of metronomic chemotherapy in the management of a cat with abdominal haemangiosarcoma. JFMS Open Rep. 2018;4(2):2055116918793455.
Gunew MN, Menrath VH, Marshall RD. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats. J Feline Med Surg. 2008;10(3):235-241.
Matsuyama A, Schott CR, Wood GA, Richardson D, Woods JP, Mutsaers AJ. Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. J Am Vet Med Assoc. 2018;252(11):1377-1383.
Patsikas MN, Papadopoulou PL, Charitanti A, et al. Computed tomography and radiographic indirect lymphography for visualization of mammary lymphatic vessels and the sentinel lymph node in normal cats. J Am Coll Vet Assoc. 2010;51(3):299-304.
Mills SW, Musil KM, Davies JL, et al. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol. 2015;52(2):238-249.
Dagher E, Abadie J, Loussouarn D, Campone M, Nguyen F. Feline invasive mammary carcinomas: prognostic value of histological grading. Vet Pathol. 2019;56(5):660-670.